{"result": "(\"entity\"<|>ALFONSO JOSÉ VIDAL CASARIEGO<|>PERSON<|>Alfonso José Vidal Casariego is a specialist in Endocrinology and Nutrition, with a Doctorate in Medicine from the University of A Coruña and currently works at the Complexo Hospitalario Universitario de A Coruña.)\n##\n(\"entity\"<|>ANA M.ª URIOSTE FONDO<|>PERSON<|>Ana M.ª Urioste Fondo is a specialist in Endocrinology and Nutrition, with advanced studies from the University of León and works as an attending physician in the Clinical Nutrition Unit.)\n##\n(\"entity\"<|>COMPLEXO HOSPITALARIO UNIVERSITARIO DE A CORUÑA<|>ORGANIZATION<|>The Complexo Hospitalario Universitario de A Coruña is a healthcare institution where specialists in Endocrinology and Nutrition provide medical services.)\n##\n(\"entity\"<|>EUROPEAN THYROID ASSOCIATION<|>ORGANIZATION<|>The European Thyroid Association is an organization that provides guidelines for the diagnosis and treatment of thyroid-related conditions, including TSH-secreting pituitary tumors.)\n##\n(\"entity\"<|>TSHOMA<|>EVENT<|>TSHoma refers to a type of pituitary tumor that secretes thyroid-stimulating hormone, which is discussed in the context of diagnosis and treatment.)\n##\n(\"relationship\"<|>ALFONSO JOSÉ VIDAL CASARIEGO<|>COMPLEXO HOSPITALARIO UNIVERSITARIO DE A CORUÑA<|>Alfonso José Vidal Casariego works at the Complexo Hospitalario Universitario de A Coruña as a specialist in Endocrinology and Nutrition.<|>8)\n##\n(\"relationship\"<|>ANA M.ª URIOSTE FONDO<|>COMPLEXO HOSPITALARIO UNIVERSITARIO DE A CORUÑA<|>Ana M.ª Urioste Fondo works at the Complexo Hospitalario Universitario de A Coruña as an attending physician in the Clinical Nutrition Unit.<|>8)\n##\n(\"relationship\"<|>ALFONSO JOSÉ VIDAL CASARIEGO<|>EUROPEAN THYROID ASSOCIATION<|>Alfonso José Vidal Casariego is involved in research and has contributed to guidelines published by the European Thyroid Association.<|>6)\n##\n(\"relationship\"<|>ANA M.ª URIOSTE FONDO<|>EUROPEAN THYROID ASSOCIATION<|>Ana M.ª Urioste Fondo may also be involved in research and clinical practices related to the guidelines set by the European Thyroid Association.<|>6)\n##\n(\"relationship\"<|>TSHOMA<|>EUROPEAN THYROID ASSOCIATION<|>The European Thyroid Association provides guidelines for the diagnosis and treatment of TSHomas, which are discussed in the context of the document.<|>7)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: %. Sin embargo,            este porcentaje         disminuye si       los tumores causantes\n\n\n\n194                                                                                                                                                                                                                                                                                             195\n---\n     son microadenomas. Así, en la serie de 43 TSHomas de Socin en la que 9 de los tumores\n     eran     microadenomas,               el   procentaje         de    positividad        de    casos      con     subunidad         α   elevada\n     era    inferior al 50%. En            cualquier       caso, la      determinación de la               subunidad         α puede aportar\n     datos significativos              en la evaluación           de este caso.\n     Se han utilizado diversas pruebas dinámicas para diferenciar la resistencia a hormonas\n     tiroideas       de los    TSHomas. La administración de T3                          exógena, 100 µg             diarios     de T3 durante\n     10 días, causa una reducción de los niveles de T4L en caso de resistencia a hormonas\n     tiroideas,       mientras       que     si  se   tratara     de    un   TSHoma         no    se   modifican        los   niveles      de    T4L.\n     Igualmente,          en   caso     de resistencia          a hormonas          tiroideas,       la  infusión de        TRH     (200     µg i.v.)\n     ocasiona un aumento de la TSH, mientras que no ocurre así en el caso de TSHomas. Por lo\n     tanto, estas pruebas pueden ayudar a diferenciar ambas entidades clínicas.\n\n\n\n                   Hipertiroidismo central            Medir TSH y T4L en familiares               Enf. familiar\n                                                                                                Enf. esporádica\n\n\n\n              Excluir interferencia metodológica                                                    Normal                              RHT\n                                                           Hacer RMN o TAC\n                                                                                                   Adenoma\n                                                          Medir SHBG y/o ICTP                       Normal\n             T4L/T3L elevada y TSH no suprimida     Hacer el cálculo subunidad a/TSH               Elevado\n\n\n\n                                                               Test TRH                      <2 veces ⬆TSH tras TRH\n                                                                                             <2 veces ⬆TSH tras TRH\n\n\n\n                                                                                                    Parcial\n                                                        Test de supresión con T3\n                                                                                                   Negativo\n\n\n\n                                                     Test de supresión con análogos                Sensible                          TSHoma\n                                                           de somatostatina                       Insensible\n\n\n\n                                                                                                   Mutación\n                                                               Gen TRb                           No mutación\n\n\n\n     Figura 2. Diagnóstico diferencial entre resistencia a hormonas tiroideas (RHT)                                                  y TSHoma.\n     Adaptado de: Beck-Peccoz P, Lania A, Beckers A, Chatterjee k, Wemeau J.-L. 2013 European Thyroid Association Guidelines for the\n     Diagnosis and Treatment of Thyrotropin-Secreting Pituitary Tumors. Eur Thyroid J. 2013;2:76-82.\n\n\n\n     Referencias:\n     •  Beck-Peccoz P, Brucker-Davis F, Persani L, Smallridge RC and Weintraub BD. Thyrotropin-secreting pituitary tumors. Endocrine Rev.\n        1996;17:610-38.\n     •  Beck-Peccoz P, Lania A, Beckers A, Chatterjee K, Wemeau.J.-L. 2013 European Thyroid Association Guidelines for the Diagnosis and\n        Treatment of Thyrotropin-Secreting Pituitary Tumors.\n        Eur Thyroid J. 2013;2:76-82.\n     •  Safer JD, Colan SD, Fraser LM, Wondisford FE. A pituitary tumor in a patient with thyroid hormone resistance: a diagnostic dilemma.\n        Thyroid. 2001;11:281-91.\n     •  Singh BK, Yen PM. A clinician’s guide to understanding resistance to thyroid hormone due to receptor mutations in the TRα and TRβ\n        isoforms. Clin Diabetes Endocrinol. 2017;3:8.\n     •  Socin HV, Chanson P, Delemer B, et al. The changing spectrum of TSH-secreting pituitary adenomas: diagnosis and management in\n        43 patients. Eur J Endocrinol. 2003;148:433-42.\n\n\n\n196\n---\nMÓDULO\n\n\n\n       4                         Nutrición\n\n\n\n          AUTORES\n          Alfonso José Vidal Casariego\n             Especialista en Endocrinología y Nutrición. Doctor en Medicina por la Univer-\n             sidad de A Coruña (2012). Máster en Metodología de la Investigación por la\n             Universidad Autónoma de Barcelona (2015).\n             Actualmente desarrolla su labor asistencial en el Complexo Hospitalario Uni-\n             versitario de A Coruña.\n             Investigador principal en 7 proyectos financiados por SACYL y producción\n             científica con múltiples presentaciones a congresos y artículos científicos\n             publicados en revistas nacionales e internacionales.\n          Ana M.ª Urioste Fondo\n             Especialista en Endocrinología y Nutrición (2005).\n             Diploma de estudios avanzados por la Universidad de León en 2006.\n             Trabaja como médico adjunto en la Unidad de Nutrición Clínica del Complejo\n             As\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}